Search

Your search keyword '"Kashimura, M."' showing total 298 results
Start Over Author "Kashimura, M."
298 results on '"Kashimura, M."'

9. Psychometric properties of the Bermond-Vorst Alexithymia Questionnaire in Japanese

Author

Kashimura, M., Ogawa, T., Vorst, H.C.M., Bermond, B., and Psychologische Methodenleer (Psychologie, FMG)

Abstract

The aim of this research is to investigate the psychometric properties of the Japanese version of the Bermond-Vorst Alexithymia Questionnaire (BVAQ-J), by testing a sample of 514 undergraduates. Explanatory factor analysis of 40 items of the BVAQ-J had a similar result to the original BVAQ (), but 10 items displayed low factor loadings (items 14, 15, 19, 25, 29, 34, 35, 36, 37, and 39); these results were slightly different from the original BVAQ. The validity and reliability of the BVAQ-30J was suggested by a significant correlation with the Toronto Alexithymia Scale-20 and estimates of test-retest and internal consistency. These results suggest that this 30-item version may be reasonably suitable for Japanese populations.

Published
2011

11. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction

Author

Shinohara, Y., primary, Takahashi, N., additional, Nishiwaki, K., additional, Hino, M., additional, Kashimura, M., additional, Wakita, H., additional, Hatano, Y., additional, Hirasawa, A., additional, Nakagawa, Y., additional, Itoh, K., additional, Masuoka, H., additional, Aotsuka, N., additional, Matsuura, Y., additional, Takahara, S., additional, Sano, K., additional, Kuroki, J., additional, Hata, T., additional, Nakamae, H., additional, Mugitani, A., additional, Nakane, T., additional, Miyazaki, Y., additional, Niioka, T., additional, Miura, M., additional, and Sawada, K., additional

Published
2013
Full Text
View/download PDF

43. Multicentric Castleman’s disease representing effusion at initial clinical presentation: clinicopathological study of seven cases.

Author

Kojima, M., Nakamura, N., Tsukamoto, N., Yokohama, A., Itoh, H., Kobayashi, S., Kashimura, M., Masawa, N., and Nakamura, S.

Subjects
CASTLEMAN'S disease, AUTOIMMUNE diseases, EXUDATES & transudates, LYMPH nodes, AUTOANTIBODY analysis, BLOOD diseases
Abstract

We present here seven cases of idiopathic multicentric Castleman’s disease (MCD) showing effusion at the initial clinical presentation. This series includes a high proportion of middle-aged and elderly females (5/7). Various autoantibodies were detected in six cases. Anemia (Hb < 10 g/dl) was detected in four cases, leukocytosis (WBC > 10 × 109/l) in three and thrombycytopenia (<100 × 109/l) in five. Positivity for C-reactive protein or elevated erythrocyte sedimentation rate was recorded in all seven cases. Elevated serum IgG level (>2000 mg/dl) was recorded in only three cases. Elevated serum interleukin-6 level was recorded in all four cases examined. At the onset of disease, four cases were associated with idiopathic thrombocytic purpura. During the course of disease, one case each was diagnosed as systemic sclerosis + Sjögren’s syndrome (SJS) and SJS. Histologically, five lesions exhibited a mixed type of Castleman’s disease, and one case each exhibited a hyaline-vascular type and plasma cell type. The non-neoplastic nature of the B-lymphocytes was demonstrated by immunohistochemistry and polymerase chain reaction. There were no human herpes type-8 virus-positive cells in any of the seven lesions. Good responsiveness to glucocorticoid therapy has been seen in all six cases treated. From a therapeutic perspective, it is important to discriminate this subtype of MCD. Lupus (2011) 20, 44—50. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

47. Clarithromycin prevents smoke-induced emphysema in mice.

Author

Nakanishi Y, Kobayashi D, Asano Y, Sakurai T, Kashimura M, Okuyama S, Yoneda Y, Shapiro SD, and Takayama K

Abstract

RATIONALE: Modulating the low-grade chronic inflammation in chronic obstructive pulmonary disease remains challenging. Clarithromycin (CAM), a macrolide antibiotic, reportedly ameliorates chronic inflammation via mechanisms independent of its antibacterial activity. OBJECTIVES: The aim of this study was to examine whether CAM can prevent or reduce emphysema induced by chronic cigarette smoke exposure. METHODS: Mice were exposed to cigarette smoke daily for 6 months and treated with orally administered CAM at doses of 25 to 100 mg/kg twice a day throughout the course of the experiment to test the preventive effects. The administration of CAM at 50 or 100 mg/kg was performed during the second half of a 6-month exposure period to assess the therapeutic effects. Histologic analysis was performed to evaluate the effect of CAM. MEASUREMENTS AND MAIN RESULTS: CAM treatment for 6 months decreased airspace enlargement and the destruction of the alveolar walls and impaired the accumulation of macrophages in bronchoalveolar lavage fluid in a dose-related fashion. The administration of clarithromycin at 100 mg/kg in the therapeutic protocol reduced emphysema compared with the smoke-exposed group without treatment. An immunohistologic analysis revealed that CAM reduced the number of F4/80-positive macrophages in the lung parenchyma. In an in vitro test, CAM at 5 to 20 microM directly suppressed the activation of macrophages stimulated with tumor necrosis factor-alpha. CONCLUSIONS: Our data demonstrated that CAM at a clinically achievable dose prevented cigarette smoke-induced emphysema by modulating lung inflammation. This study supports the possibility that low-dose CAM treatment might provide a new therapeutic strategy for chronic obstructive pulmonary diseases. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results